Trials / Completed
CompletedNCT00049751
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,000 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab |
Timeline
- Start date
- 2002-09-01
- First posted
- 2002-11-14
- Last updated
- 2006-08-15
Locations
54 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00049751. Inclusion in this directory is not an endorsement.